Medicare's $50 GLP-1 Bridge: Who Qualifies, What's Covered and What's Left Out

For the first time, people with Medicare drug coverage can get Wegovy, Foundayo or the Zepbound KwikPen for weight loss for a flat $50 a month, but only if they clear a set of clinical rules, and only until 31 December 2027. The Medicare GLP-1 Bridge is a temporary federal demonstration that began on 1 July 2026. It sits outside normal Part D drug coverage, which by law still cannot pay for drugs used for weight loss.¹³⁷

That design explains most of the surprises people run into: who is turned away, why the $50 does not count toward the yearly cap, and why Extra Help does not lower it. Below is what the program covers, who qualifies, what is left out and what is still unclear. Nothing here is medical or insurance advice, and this article gives no dosing information.

Why Medicare needed a workaround

Part D, Medicare's drug benefit, excludes the same classes of drugs that Medicaid law lets states leave out. The first item on that list is "agents when used for anorexia, weight loss, or weight gain."⁷ Medicare has therefore been "prohibited by law" from covering drugs used specifically for weight loss since Part D began, as KFF puts it.⁴

GLP-1 drugs could already be covered for other approved uses. Semaglutide as Ozempic is covered for type 2 diabetes, and Wegovy can be covered when it is prescribed to cut the risk of heart attack and stroke; our overview of GLP-1 drugs beyond weight loss explains those other uses. Weight loss on its own was the gap.

The Bridge does not change the law. CMS runs it under a demonstration power from 1967 that lets the government test changes in how it pays for care, applied to Part D through the Social Security Act.¹ KFF notes that the program "does not change the current statutory prohibition on Medicare coverage of drugs used for weight loss."⁵

What is covered, and what is not

CMS lists three products:¹²³

• Foundayo (orforglipron), the daily tablet, in all its forms.
• Wegovy (semaglutide), as the weekly injection and as the daily tablet.
• Zepbound (tirzepatide), KwikPen only.

Two Zepbound forms are excluded: the single-dose vials and the single-dose pens.²³ Pen needles are not covered either, and CMS tells pharmacies not to bill them to the Bridge or the Part D plan.² No other GLP-1 is included, and compounded versions are not part of the program. CMS publishes the eligible products as a list of national drug codes and says it "may be updated", most recently in April 2026 to add Foundayo.² If you use a less common pen, such as the newer Wegovy HD covered in our Zepbound vs Wegovy HD article, ask the pharmacy to check it against that list; CMS's page does not name pen strengths.

Who qualifies

You must be 18 or older and have Medicare drug coverage through a standalone Part D plan or a Medicare Advantage plan with drug coverage. Special needs plans, employer group plans and the LI NET program are included, and people with both Medicare and Medicaid can qualify. A few less common plan types, such as private fee-for-service and PACE, are excluded unless the person also has a standalone Part D plan.²³

The drug must be prescribed to reduce excess weight and keep it off, alongside a lifestyle program focused on diet and exercise.²³ Then one of three clinical tests has to be met, judged at the time the GLP-1 was first started:²

Source: CMS information for prescribers, updated 6 August 2026²; Medicare.gov³.

The "when you started" rule matters for anyone already taking one of these drugs and paying cash. CMS gives the example of a patient whose body mass index was 37 when treatment began and is now 34: that person qualifies on the starting figure. The prescriber attests to this under penalty of perjury, and CMS says it may check claims against Medicare data.²

Who is sent back to their regular plan

Some people who meet the weight criteria are still turned away, because their use is one Part D can already cover:²³

• Type 2 diabetes, moderate-to-severe obstructive sleep apnoea and noncirrhotic MASH (a form of fatty liver disease). These go through the person's Part D plan, even if the Bridge criteria are met.
• Heart-risk reduction. If the GLP-1 is prescribed to lower the risk of major cardiovascular events, the claim belongs with the Part D plan.
• Anyone already getting a GLP-1 covered by their Part D plan.

That routing can cost more, not less. Through the plan, a person pays whatever the plan's cost-sharing is, which may be more than $50 a month.⁶ Prediabetes, by contrast, is one of the qualifying conditions.

What you pay, and what the $50 does not count toward

The price at the pharmacy counter is $50 for a one-month supply (28 or 30 days, depending on the product), whatever the dose.³⁶ The Part D deductible does not apply.¹ Behind that, manufacturers agreed to a net price of $245 per 30-day supply, so Medicare pays the difference.⁴

Because the Bridge runs outside the Part D benefit, the $50:¹³

• does not count toward the Part D deductible or the yearly out-of-pocket limit, which is $2,100 in 2026 and rises to $2,400 in 2027⁴;
• will not appear on your Part D statement or Medicare Summary Notice;
• cannot be lowered by Extra Help, the low-income subsidy;
• cannot be spread over the year through the Medicare Prescription Payment Plan.

Manufacturer coupons and discounts cannot be applied to Bridge claims.⁸ For someone on Extra Help used to paying a few dollars per prescription, $50 a month may be the main barrier.⁶

How it works in practice

There is no separate sign-up.³⁸ The steps CMS describes are:²³

1. The prescriber sends a prescription for a covered product to the pharmacy. CMS says the prescription must come first; a prior authorization sent before the pharmacy has filed a claim is rejected because the system cannot find the patient.
2. The pharmacy submits the claim, and a prior authorization request goes back to the prescriber, usually within 24 to 72 hours.
3. A single central processor handles prior authorization, claims and payments to pharmacies in 2026. Reporting by KFF Health News and AJMC identifies it as Humana, which already runs Medicare's LI NET program.¹⁶⁸
4. Decisions go to the prescriber, and the patient receives a letter confirming coverage.

According to Medicare.gov, an approval "is valid (including for refills and dose changes) through December 31, 2027, unless you change GLP-1s."³ There is no appeals process. A prescriber can resubmit the form to fix errors or add information.² Prescribers do not need to be enrolled in Medicare, but they must not be on Medicare's preclusion list.² For eligibility questions, Medicare's helpline is 1-800-MEDICARE (1-800-633-4227; TTY 1-877-486-2048).¹³

How many people this reaches

Far fewer than the number of older Americans with obesity. KFF estimated, using 2023 claims, that 13.3 million Medicare beneficiaries had a recorded body mass index of 27 or more. About 9.7 million Part D enrollees met the clinical criteria, but only 3.8 million (39% of them) were likely eligible once people with type 2 diabetes, sleep apnoea or MASH, and those already filling a Part D-covered GLP-1, were removed.⁵ KFF put Medicare's cost at $1.3 billion to $3.3 billion over the 18 months if 10% to 25% of eligible people took part.⁵

CMS has not published enrolment figures. We could not find any official count of approvals as of 3 November 2026.

What happens after 2027

This is the biggest unknown. The Bridge was first planned to run only until the end of 2026.⁶ It was meant to lead into the BALANCE Model, a voluntary arrangement under which Part D plans and state Medicaid programs could cover GLP-1s for weight loss at negotiated prices.⁴

On 21 April 2026 CMS said the Part D side of BALANCE would not go ahead in 2027; KFF reports that the required level of plan participation was not reached. CMS extended the Bridge to 31 December 2027 instead, to gather data it can share with insurers before any later Part D launch.¹⁴ No new start date has been announced. KFF's conclusion is blunt: without another extension or a working BALANCE Model, beneficiaries could lose this coverage in 2028.⁴

The Medicaid side of BALANCE went ahead separately, with states able to start between May 2026 and January 2027. Coverage there is a state choice: KFF counted 13 state Medicaid programs covering GLP-1s for obesity in January 2026, down from 16 in 2025.⁴

If you start a GLP-1 through the Bridge, it is worth knowing what happens if coverage ends. Our guide to stopping semaglutide or tirzepatide covers weight regain after stopping, and not losing weight on a GLP-1 covers what trials count as a normal response.

If you don't qualify

Medicare.gov points people who are not eligible to manufacturer assistance programs, state drug-cost programs, mail-order price comparisons and the government's TrumpRx.gov cash-price site, noting that discount cards there do not count toward the Part D deductible or out-of-pocket limit.³ Cash prices vary by product and dose; KFF Health News reported a range of roughly $149 to $699 a month in May 2026.⁶

Cheaper compounded or online versions are not covered by the Bridge, and they are not the same as the approved products. FDA inspections of ingredient factories and a run of recalls show why quality is a concern; see our articles on compounded GLP-1 supply problems and FDA's plan to end bulk compounding. For investigational drugs, joining a trial is the legal route.

We will update this article if CMS changes the product list, extends the Bridge or announces a start date for the Part D side of BALANCE.